215 related articles for article (PubMed ID: 34507995)
1. Rational design of ASCT2 inhibitors using an integrated experimental-computational approach.
Garibsingh RA; Ndaru E; Garaeva AA; Shi Y; Zielewicz L; Zakrepine P; Bonomi M; Slotboom DJ; Paulino C; Grewer C; Schlessinger A
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507995
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.
Yu X; Plotnikova O; Bonin PD; Subashi TA; McLellan TJ; Dumlao D; Che Y; Dong YY; Carpenter EP; West GM; Qiu X; Culp JS; Han S
Elife; 2019 Oct; 8():. PubMed ID: 31580259
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM structure of the human neutral amino acid transporter ASCT2.
Garaeva AA; Oostergetel GT; Gati C; Guskov A; Paulino C; Slotboom DJ
Nat Struct Mol Biol; 2018 Jun; 25(6):515-521. PubMed ID: 29872227
[TBL] [Abstract][Full Text] [Related]
4. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
5. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.
Colas C; Grewer C; Otte NJ; Gameiro A; Albers T; Singh K; Shere H; Bonomi M; Holst J; Schlessinger A
PLoS Comput Biol; 2015 Oct; 11(10):e1004477. PubMed ID: 26444490
[TBL] [Abstract][Full Text] [Related]
6. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.
Schulte ML; Khodadadi AB; Cuthbertson ML; Smith JA; Manning HC
Bioorg Med Chem Lett; 2016 Feb; 26(3):1044-1047. PubMed ID: 26750251
[TBL] [Abstract][Full Text] [Related]
7. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
8. Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2.
Singh K; Tanui R; Gameiro A; Eisenberg G; Colas C; Schlessinger A; Grewer C
Bioorg Med Chem Lett; 2017 Feb; 27(3):398-402. PubMed ID: 28057420
[TBL] [Abstract][Full Text] [Related]
9. Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5.
Scopelliti AJ; Font J; Vandenberg RJ; Boudker O; Ryan RM
Nat Commun; 2018 Jan; 9(1):38. PubMed ID: 29295993
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the neutral amino acid transporter ASCT2 with basic amino acids.
Ndaru E; Garibsingh RA; Zielewicz L; Schlessinger A; Grewer C
Biochem J; 2020 Apr; 477(8):1443-1457. PubMed ID: 32242892
[TBL] [Abstract][Full Text] [Related]
11. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity.
Oppedisano F; Catto M; Koutentis PA; Nicolotti O; Pochini L; Koyioni M; Introcaso A; Michaelidou SS; Carotti A; Indiveri C
Toxicol Appl Pharmacol; 2012 Nov; 265(1):93-102. PubMed ID: 23010140
[TBL] [Abstract][Full Text] [Related]
13. Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2.
Garibsingh RA; Otte NJ; Ndaru E; Colas C; Grewer C; Holst J; Schlessinger A
Front Chem; 2018; 6():279. PubMed ID: 30137742
[TBL] [Abstract][Full Text] [Related]
14. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
15. Physical and functional interactions between the serotonin transporter and the neutral amino acid transporter ASCT2.
Seyer P; Vandermoere F; Cassier E; Bockaert J; Marin P
Biochem J; 2016 Jul; 473(13):1953-65. PubMed ID: 27143784
[TBL] [Abstract][Full Text] [Related]
16. Cysteine 467 of the ASCT2 Amino Acid Transporter Is a Molecular Determinant of the Antiport Mechanism.
Scalise M; Pappacoda G; Mazza T; Console L; Pochini L; Indiveri C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163050
[TBL] [Abstract][Full Text] [Related]
17. A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2.
Garaeva AA; Guskov A; Slotboom DJ; Paulino C
Nat Commun; 2019 Jul; 10(1):3427. PubMed ID: 31366933
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Synthesis of Hydroxy-l-Proline Blockers of the Neutral Amino Acid Transporters SLC1A4 (ASCT1) and SLC1A5 (ASCT2).
Lyda BR; Leary GP; Farnsworth J; Seaver B; Silvius D; Kavanaugh MP; Esslinger CS; Natale NR
Molecules; 2024 May; 29(10):. PubMed ID: 38792190
[TBL] [Abstract][Full Text] [Related]
19. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
20. Ablation of the
Bröer A; Gauthier-Coles G; Rahimi F; van Geldermalsen M; Dorsch D; Wegener A; Holst J; Bröer S
J Biol Chem; 2019 Mar; 294(11):4012-4026. PubMed ID: 30635397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
